Maze Therapeutics (NASDAQ:MAZE) Earns Buy Rating from BTIG Research

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a note issued to investors on Tuesday, September 22nd, Benzinga reports. They currently have a $46.00 target price on the stock. BTIG Research’s target price indicates a potential upside of 70.24% from the stock’s current price.

A number of other research analysts have also weighed in on MAZE. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Finally, TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and a consensus target price of $63.40.

Maze Therapeutics Stock Up 0.6%

Shares of MAZE stock traded up $0.17 during trading hours on Tuesday, reaching $27.02. The company had a trading volume of 709,489 shares, compared to its average volume of 667,022. Maze Therapeutics has a 12 month low of $21.95 and a 12 month high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The business has a fifty day simple moving average of $27.09 and a 200-day simple moving average of $28.74. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -10.72 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, research analysts expect that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total value of $52,332.12. Following the completion of the sale, the insider directly owned 7,007 shares of the company’s stock, valued at $182,252.07. This trade represents a 22.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Atul Dandekar sold 3,243 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total value of $84,350.43. Following the completion of the sale, the insider directly owned 32,316 shares of the company’s stock, valued at $840,539.16. This represents a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 183,959 shares of company stock valued at $5,053,389. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Maze Therapeutics

A number of large investors have recently bought and sold shares of MAZE. TRV GP IV LLC purchased a new stake in Maze Therapeutics in the second quarter worth $133,502,907. ARCH Venture Management LLC purchased a new stake in Maze Therapeutics in the second quarter worth $122,983,582. BlackRock Inc. purchased a new stake in Maze Therapeutics in the second quarter worth $104,525,000. Jupiter Topco LLC purchased a new stake in Maze Therapeutics in the second quarter worth $101,764,000. Finally, Alphabet Inc. purchased a new position in shares of Maze Therapeutics in the second quarter valued at $41,435,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.